Caris Life Sciences, Inc. (CAI)

NMS – Real vaqt narxi. Valyuta: USD

22.26

-0.88 (-3.80%)

Yopilishda: Aug 12, 2026, 4:00 PM EDT

22.50

+0.24 (1.08%)

Bozordan keyin: Aug 12, 2026, 4:10 PM EDT

07.08.2026

Caris Life Sciences: Guidance Raised, Valuation Still Attractive

Caris Life Sciences delivered another strong quarter, raising full-year guidance and expanding margins while sustaining positive free cash flow. Accelerating clinical volume growth and the commercial launch of Caris Detect reinforce the durability and breadth of CAI's growth drivers. Valuation remains attractive and CAI trades at a discount to peers, with a fair value estimate of $30 per share by 2028.

06.08.2026

Caris Life Sciences, Inc. (CAI) Q2 2026 Earnings Call Transcript

05.08.2026

Caris Life Sciences,?Inc. (CAI) Reports Break-Even Earnings for Q2

Caris Life Sciences,?Inc. (CAI) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to a loss of $0.54 per share a year ago.

05.08.2026

Caris Life Sciences Q2 Earnings Call Highlights

Caris Life Sciences NASDAQ: CAI reported record clinical volume and raised its full-year revenue outlook after second-quarter revenue increased 45% from a year earlier, driven by growth in molecular profiling services, higher average selling prices and an expanding commercial organization.

05.08.2026

Caris Life Sciences Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance

Revenue growth of 45% driven by strong performance in molecular profiling services, including approximately 59,200 clinical cases, consisting of over 114,000 whole exome/whole transcriptome tests with over 345,000 total oncology tests Raises 2026 revenue guidance to $1.03 to $1.04 billion, representing growth of 27% to 28% IRVING, Texas, Aug. 5, 2026 /PRNewswire/ -- Caris Life Sciences, Inc. (Nasdaq: CAI), a leading TechBio company actively developing and commercializing solutions to transform healthcare, today reported financial results for the quarter ended June 30, 2026. Second Quarter 2026 Financial Highlights Reported total revenue of $263.7 million, an increase of 45% over the corresponding prior year period.

Videolar

No Data

There is no data to display

Press-relizlar

05.08.2026

Caris Life Sciences, Inc. (CAI)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Caris Life Sciences, Inc. (CAI)

Caris Life Sciences: Guidance Raised, Valuation Still Attractive

Caris Life Sciences, Inc. (CAI) Q2 2026 Earnings Call Transcript

Caris Life Sciences,?Inc. (CAI) Reports Break-Even Earnings for Q2

Caris Life Sciences Q2 Earnings Call Highlights

Caris Life Sciences Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance

Videolar

No Data

Press-relizlar

Caris Life Sciences Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance

Caris Life Sciences: Guidance Raised, Valuation Still Attractive

Caris Life Sciences, Inc. (CAI) Q2 2026 Earnings Call Transcript

Caris Life Sciences,?Inc. (CAI) Reports Break-Even Earnings for Q2

Caris Life Sciences Q2 Earnings Call Highlights

Caris Life Sciences Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance

Videolar

No Data

Press-relizlar

Caris Life Sciences Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance

Search stocks

Caris Life Sciences, Inc. (CAI)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Caris Life Sciences, Inc. (CAI)

Caris Life Sciences: Guidance Raised, Valuation Still Attractive

Caris Life Sciences, Inc. (CAI) Q2 2026 Earnings Call Transcript

Caris Life Sciences,?Inc. (CAI) Reports Break-Even Earnings for Q2

Caris Life Sciences Q2 Earnings Call Highlights

Caris Life Sciences Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance

Videolar

No Data

Press-relizlar

Caris Life Sciences Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance

Caris Life Sciences: Guidance Raised, Valuation Still Attractive

Caris Life Sciences, Inc. (CAI) Q2 2026 Earnings Call Transcript

Caris Life Sciences,?Inc. (CAI) Reports Break-Even Earnings for Q2

Caris Life Sciences Q2 Earnings Call Highlights

Caris Life Sciences Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance

Videolar

No Data

Press-relizlar

Caris Life Sciences Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance